Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period.

Trial Profile

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SCALE; SCALE-Diabetes
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Nov 2016 Results of population pharmacokinetic analysis in obese patients of this and other two trials published in the Clinical Pharmacokinetics
    • 19 May 2016 Results of a post-hoc population pharmacokinetic analysis from SCALE-Diabetes and SCALE-Obesity and Pre-diabetes trials (n=2923) published in the Clinical Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top